Fundraising FoxScienture Holdings
NASDAQ: SCNXTampa, US · Delaware corporation
Find your way into Scienture Holdings
Sign up to see every warm intro you have to Scienture Holdings
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Scienture Holdings team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Scienture Holdings operates and manages pharmaceutical companies that develop and commercialize specialty pharmaceutical products for underserved patient populations. The company focuses on addressing unmet medical needs through novel drug concepts, manufacturing expertise, and integrated sales and marketing capabilities.
Founders & leadership
SA
Suren AjjarapuFounder
SH
Shankar HariharanExecutive
HD
Howard DossChief Financial Officer
PP
Prashant PatelNamed on SEC filing
SA
Surendra AjjarapuNamed on SEC filing
Board
MD
Mayur DoshiBoard director
DF
Donald FellBoard director
SJ
Subbarao JayanthiBoard director
FS
Fernando SanchezBoard director
CL
Charles L. PopeBoard director
Reported raises · per SEC filings
Form D private placements$74.2M disclosed across 11 of 13 rounds · 2014–2026
▶$1.7MraisedAug 2025 · 8 investors · PharmaceuticalsRule 506(b)
▶$1.7MraisedAug 2025 · 8 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Donald G. FellDirector
- Subbarao JayanthiDirector
- Shankar HariharanExecutive Officer, Director
- Narasimhan ManiExecutive Officer, Director
- Mayur DoshiDirector
- Offering amount
- $3M
- Amount sold
- $1.7M
- Minimum investment
- $50K
- Sales commissions
- $35K
- Placement agents
- Finalis Securities LLC
- First sale
- Jul 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b, 4a5
▶$3.3MraisedDec 2024 · 2 investors · PharmaceuticalsRule 506(b)
▶$3.3MraisedDec 2024 · 2 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Prashant PatelExecutive Officer, Director
- Narasimhan ManiDirector
- Shankar HariharanDirector
- Mayur DoshiDirector
- Donald FellDirector
- Surendra AjjarapuExecutive Officer, Director
- Subbarao JayanthiDirector
- Offering amount
- $3.3M
- Amount sold
- $3.3M
- Sales commissions
- $210K
- First sale
- Nov 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1MraisedAug 2019 · 1 investors · PharmaceuticalsRule 506(b)
▶$1MraisedAug 2019 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Prashant PatelExecutive Officer, Director
- Donald FellDirector
- Howard DossExecutive Officer
- Michael PetersonDirector
- Suren AjjarapuExecutive Officer, Director
- Offering amount
- $2M
- Amount sold
- $1M
- Minimum investment
- $500K
- First sale
- Jul 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$500KraisedNov 2018 · 1 investors · PharmaceuticalsRule 506(b)
▶$500KraisedNov 2018 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Donald FellDirector
- Howard DossExecutive Officer
- Prashant PatelExecutive Officer, Director
- Suren AjjarapuExecutive Officer, Director
- Michael PetersonDirector
- Offering amount
- $1M
- Amount sold
- $500K
- Minimum investment
- $50K
- First sale
- Nov 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$300KraisedOct 2018 · 1 investors · PharmaceuticalsRule 506(b)
▶$300KraisedOct 2018 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Michael PetersonDirector
- Donald FellDirector
- Prashant PatelExecutive Officer, Director
- Howard DossExecutive Officer
- Suren AjjarapuExecutive Officer, Director
- Offering amount
- $300K
- Amount sold
- $300K
- Minimum investment
- $25K
- First sale
- Oct 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$300KraisedJul 2018 · 2 investors · PharmaceuticalsRule 506(b)
▶$300KraisedJul 2018 · 2 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Howard DossExecutive Officer
- Donald FellDirector
- Suren AjjarapuExecutive Officer, Director
- Michael PetersonDirector
- Prashant PatelExecutive Officer, Director
- Offering amount
- $2M
- Amount sold
- $300K
- Minimum investment
- $25K
- First sale
- Jul 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$250.9KraisedMar 2017 · 1 investors · PharmaceuticalsRule 506(b)
▶$250.9KraisedMar 2017 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Suren AjjarapuExecutive Officer, Director
- Michael L PetersonDirector
- Howard DossExecutive Officer
- Donald FellDirector
- Prashant PatelExecutive Officer, Director
- Offering amount
- $250.9K
- Amount sold
- $250.9K
- First sale
- Feb 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$15KofferedJan 2017 · 1 investors · PharmaceuticalsRule 506(b)
▶$15KofferedJan 2017 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Prashant PatelExecutive Officer, Director
- Michael L PetersonDirector
- Howard DossExecutive Officer
- Suren AjjarapuExecutive Officer, Director
- Donald FellDirector
- Offering amount
- $15K
- First sale
- Dec 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed events$42.5Mvaluation at IPOFeb 2020 · $6.50/share · 424B4
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Related companies · 7
NasdaqNasdaq operates a technology infrastructure platform for financial markets across three business segments: Capital Access Platforms (which includes listing services, indices, and analytics tools), Financial Technology (comprising compliance, regulatory, and capital markets software), and Market Services (equities and derivatives trading operations). The company serves financial institutions, listed companies, investment managers, and regulatory agencies globally.
RobinhoodRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Seeking AlphaSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
StockTwitsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.
TradingViewTradingView is a charting platform and social network used by over 100 million traders and investors worldwide to analyze and trade across global financial markets. The platform provides tools for technical analysis, market data, and community collaboration for retail and institutional traders.
PublicPublic is a trading platform that allows users to buy and sell cryptocurrencies including Bitcoin, Ethereum, and memecoins through accounts managed by Zero Hash LLC, a New York State-licensed virtual currency business.
TipRanksFinancial analysis and stock research platform.
Companies working in the same space as Scienture Holdings.
Frequently asked questions
- What does Scienture Holdings do?
- Scienture Holdings operates and manages pharmaceutical companies that develop and commercialize specialty pharmaceutical products for underserved patient populations. The company focuses on addressing unmet medical needs through novel drug concepts, manufacturing expertise, and integrated sales and marketing capabilities.
- Who founded Scienture Holdings?
- Scienture Holdings was founded by Suren Ajjarapu.
- How much funding has Scienture Holdings raised?
- Scienture Holdings has disclosed $74.2M raised across 11 of its 13 known rounds.
- Where is Scienture Holdings headquartered?
- Scienture Holdings is headquartered in Tampa, US.